Haemonetics (HAE) Stock Forecast, Price Target & Predictions
HAE Stock Forecast
Haemonetics stock forecast is as follows: an average price target of $108.25 (represents a 22.77% upside from HAE’s last price of $88.17) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HAE Price Target
The average price target for Haemonetics (HAE) is $108.25 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $85.00. This represents a potential 22.77% upside from HAE's last price of $88.17.
HAE Analyst Ratings
According to 7 Wall Street analysts, Haemonetics's rating consensus is 'Buy'. The analyst rating breakdown for HAE stock is 1 'Strong Buy' (14.29%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haemonetics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Andrew Cooper | Raymond James | $120.00 | $74.83 | 60.36% | 36.10% |
| Sep 13, 2024 | Kristen Stewart | C.L. King | $116.00 | $73.26 | 58.34% | 31.56% |
| Sep 11, 2024 | Craig Bijou | Bank of America Securities | $85.00 | $71.61 | 18.69% | -3.60% |
| Jun 12, 2024 | Mike Matson | Needham | $112.00 | $83.41 | 34.28% | 27.03% |
The latest Haemonetics stock forecast, released on Nov 08, 2024 by Andrew Cooper from Raymond James, set a price target of $120.00, which represents a 60.36% increase from the stock price at the time of the forecast ($74.83), and a 36.10% increase from HAE last price ($88.17).
Haemonetics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 4 |
| Avg Price Target | $120.00 | $107.00 | $108.25 |
| Last Closing Price | $88.17 | $88.17 | $88.17 |
| Upside/Downside | 36.10% | 21.36% | 22.77% |
In the current month, the average price target of Haemonetics stock is $120.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 36.10% increase as opposed to Haemonetics's last price of $88.17. This month's average price target is up 12.15% compared to last quarter, and up 10.85% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 08, 2024 | Raymond James | - | Strong Buy | Upgrade |
| Sep 11, 2024 | Bank of America Securities | - | Neutral | Initialise |
| Sep 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 10, 2024 | Citigroup | Underperform | Underperform | Hold |
| Sep 10, 2024 | BTIG | - | Buy | Initialise |
| Aug 22, 2024 | Needham | Market Outperform | Market Outperform | Hold |
| Jun 12, 2024 | Needham | Hold | Buy | Upgrade |
| May 10, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| May 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jun 12, 2023 | William Blair | Outperform | Outperform | Hold |
Haemonetics's last stock rating was published by Raymond James on Nov 08, 2024. The company Upgrade its HAE rating from "null" to "Strong Buy".
Haemonetics Financial Forecast
Haemonetics Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $336.25M | $318.18M | $311.33M | $304.42M | $305.30M | $297.49M | $261.46M | $265.00M | - | $239.90M | $228.53M | $225.03M | $240.37M | $209.49M | $195.58M | $238.49M | $258.97M |
| Avg Forecast | $413.73M | $388.88M | $377.36M | $365.13M | $377.95M | $365.15M | $356.07M | $347.19M | $359.02M | $353.90M | $342.57M | $335.08M | $329.53M | $320.84M | $313.15M | $292.74M | $290.79M | $299.56M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| High Forecast | $421.24M | $395.93M | $384.21M | $371.75M | $384.80M | $371.78M | $362.53M | $353.49M | $368.24M | $358.23M | $342.75M | $335.08M | $329.53M | $325.06M | $319.83M | $298.05M | $296.06M | $304.99M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| Low Forecast | $407.92M | $383.41M | $372.06M | $360.00M | $372.64M | $360.02M | $351.06M | $342.31M | $355.36M | $348.87M | $342.39M | $335.08M | $329.53M | $318.18M | $309.03M | $288.63M | $286.70M | $295.35M | $269.22M | $249.00M | $257.11M | $265.39M | $240.84M | $219.43M | $222.98M | $224.26M | $207.65M | $198.27M | $246.53M | $255.40M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.02% | 1.06% | 1.05% | 1.02% | 1.10% | 1.05% | 1.03% | - | 1.00% | 1.04% | 1.01% | 1.07% | 1.01% | 0.99% | 0.97% | 1.01% |
Haemonetics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $329.53M, with a low forecast of $329.53M, and a high forecast of $329.53M. HAE's average Quarter revenue forecast represents a -2.00% decrease compared to the company's last Quarter revenue of $336.25M (Dec 23).
Haemonetics EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $69.51M | $35.30M | $53.66M | $59.11M | $66.85M | $69.79M | $53.21M | $31.26M | - | $48.04M | $7.22M | $536.00K | $39.31M | $48.16M | $33.47M | $54.77M | $69.84M |
| Avg Forecast | $84.73M | $79.64M | $77.29M | $74.78M | $77.41M | $74.79M | $72.92M | $71.11M | $73.53M | $72.48M | $70.16M | $68.63M | $48.82M | $65.71M | $64.14M | $59.96M | $44.38M | $74.38M | $56.43M | $52.19M | $40.34M | $55.63M | $50.48M | $45.99M | $965.37K | $47.01M | $43.52M | $41.56M | $57.77M | $53.53M |
| High Forecast | $86.27M | $81.09M | $78.69M | $76.14M | $78.81M | $76.14M | $74.25M | $72.40M | $75.42M | $73.37M | $70.20M | $68.63M | $58.58M | $66.57M | $65.50M | $61.04M | $53.25M | $89.25M | $56.43M | $52.19M | $48.41M | $55.63M | $50.48M | $45.99M | $1.16M | $47.01M | $43.52M | $41.56M | $69.33M | $53.53M |
| Low Forecast | $83.54M | $78.52M | $76.20M | $73.73M | $76.32M | $73.73M | $71.90M | $70.11M | $72.78M | $71.45M | $70.12M | $68.63M | $39.05M | $65.17M | $63.29M | $59.11M | $35.50M | $59.50M | $56.43M | $52.19M | $32.28M | $55.63M | $50.48M | $45.99M | $772.30K | $47.01M | $43.52M | $41.56M | $46.22M | $53.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 0.55% | 0.89% | 1.33% | 0.90% | 1.24% | 1.02% | 0.77% | - | 0.95% | 0.16% | 0.56% | 0.84% | 1.11% | 0.81% | 0.95% | 1.30% |
2 analysts predict HAE's average Quarter EBITDA for Mar 24 to be $48.82M, with a high of $58.58M and a low of $39.05M. This is -29.77% lower than Haemonetics's previous annual EBITDA (Dec 23) of $69.51M.
Haemonetics Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $31.24M | $24.91M | $41.04M | $29.38M | $32.94M | $33.20M | $19.88M | $9.74M | - | $14.86M | $-4.45M | $-11.04M | $31.88M | $48.10M | $10.53M | $17.62M | $29.89M |
| Avg Forecast | $90.09M | $82.47M | $75.15M | $69.82M | $75.15M | $69.86M | $65.84M | $60.84M | $65.81M | $60.21M | $54.99M | $51.52M | $10.80M | $48.24M | $45.49M | $37.04M | $9.82M | $7.74K | $34.74M | $26.30M | $8.93M | $37.83M | $31.24M | $23.20M | $-14.50M | $33.74M | $26.05M | $21.36M | $18.59M | $39.04M |
| High Forecast | $92.22M | $84.41M | $76.92M | $71.47M | $76.92M | $71.50M | $67.39M | $62.27M | $67.38M | $61.21M | $55.09M | $51.53M | $12.97M | $49.73M | $49.58M | $37.92M | $11.79M | $9.29K | $34.74M | $26.30M | $10.72M | $37.83M | $31.24M | $23.20M | $-11.60M | $33.74M | $26.05M | $21.36M | $22.31M | $39.04M |
| Low Forecast | $88.44M | $80.96M | $73.78M | $68.54M | $73.78M | $68.58M | $64.64M | $59.73M | $63.72M | $59.20M | $54.89M | $51.51M | $8.64M | $47.25M | $42.43M | $36.37M | $7.86M | $6.20K | $34.74M | $26.30M | $7.14M | $37.83M | $31.24M | $23.20M | $-17.40M | $33.74M | $26.05M | $21.36M | $14.87M | $39.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.65% | 0.55% | 1.11% | 2.99% | 4254.68% | 0.96% | 0.76% | 1.09% | - | 0.48% | -0.19% | 0.76% | 0.94% | 1.85% | 0.49% | 0.95% | 0.77% |
Haemonetics's average Quarter net income forecast for Mar 24 is $10.80M, with a range of $8.64M to $12.97M. HAE's average Quarter net income forecast represents a -65.42% decrease compared to the company's last Quarter net income of $31.24M (Dec 23).
Haemonetics SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $111.71M | $104.90M | $93.48M | $97.38M | $94.66M | $92.41M | $92.23M | $91.84M | - | $75.78M | $91.22M | $83.71M | $73.45M | $71.70M | $69.54M | $78.57M | $78.27M |
| Avg Forecast | $133.40M | $125.39M | $121.68M | $117.73M | $121.87M | $117.74M | $114.81M | $111.95M | $115.76M | $114.11M | $110.46M | $108.04M | $101.87M | $103.45M | $100.97M | $94.39M | $92.61M | $78.14M | $86.17M | $79.69M | $84.19M | $84.94M | $77.08M | $70.23M | $78.16M | $71.78M | $66.46M | $63.46M | $82.88M | $81.74M |
| High Forecast | $135.82M | $127.66M | $123.89M | $119.87M | $124.08M | $119.88M | $116.89M | $113.98M | $118.73M | $115.51M | $110.52M | $108.04M | $122.24M | $104.81M | $103.13M | $96.10M | $111.13M | $93.77M | $86.17M | $79.69M | $101.03M | $84.94M | $77.08M | $70.23M | $93.79M | $71.78M | $66.46M | $63.46M | $99.46M | $81.74M |
| Low Forecast | $131.53M | $123.63M | $119.97M | $116.08M | $120.15M | $116.09M | $113.20M | $110.38M | $114.58M | $112.49M | $110.40M | $108.04M | $81.49M | $102.60M | $99.64M | $93.07M | $74.09M | $62.51M | $86.17M | $79.69M | $67.35M | $84.94M | $77.08M | $70.23M | $62.53M | $71.78M | $66.46M | $63.46M | $66.30M | $81.74M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.04% | 0.99% | 1.05% | 1.21% | 1.07% | 1.16% | 1.09% | - | 0.98% | 1.30% | 1.07% | 1.02% | 1.08% | 1.10% | 0.95% | 0.96% |
Haemonetics's average Quarter SG&A projection for Mar 24 is $101.87M, based on 2 Wall Street analysts, with a range of $81.49M to $122.24M. The forecast indicates a -8.81% fall compared to HAE last annual SG&A of $111.71M (Dec 23).
Haemonetics EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 | 7 | 7 | 3 | 2 | 2 | 3 | 6 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 10 | 10 | 10 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.62 | $0.49 | $0.81 | $0.58 | $0.65 | $0.65 | $0.39 | $0.19 | - | $0.29 | $-0.09 | $-0.22 | $0.63 | $0.95 | $0.21 | $0.34 | $0.59 |
| Avg Forecast | $1.76 | $1.61 | $1.47 | $1.36 | $1.47 | $1.36 | $1.28 | $1.19 | $1.28 | $1.17 | $1.07 | $1.01 | $0.89 | $0.94 | $0.89 | $0.72 | $0.70 | $0.82 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| High Forecast | $1.80 | $1.65 | $1.50 | $1.39 | $1.50 | $1.40 | $1.32 | $1.22 | $1.31 | $1.19 | $1.08 | $1.01 | $0.89 | $0.97 | $0.97 | $0.74 | $0.72 | $0.84 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| Low Forecast | $1.73 | $1.58 | $1.44 | $1.34 | $1.44 | $1.34 | $1.26 | $1.17 | $1.24 | $1.16 | $1.07 | $1.01 | $0.89 | $0.92 | $0.83 | $0.71 | $0.69 | $0.80 | $0.67 | $0.51 | $0.60 | $0.73 | $0.61 | $0.45 | $0.67 | $0.65 | $0.51 | $0.41 | $0.73 | $0.76 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.55% | 1.12% | 0.82% | 0.80% | 0.96% | 0.76% | 0.32% | - | 0.48% | -0.19% | -0.33% | 0.96% | 1.88% | 0.51% | 0.47% | 0.78% |
According to 2 Wall Street analysts, Haemonetics's projected average Quarter EPS for Mar 24 is $0.89, with a low estimate of $0.89 and a high estimate of $0.89. This represents a 43.84% increase compared to HAE previous annual EPS of $0.62 (Dec 23).
Haemonetics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| COO | Cooper Companies | $99.48 | $298.00 | 199.56% | Buy |
| AKYA | Akoya Biosciences | $2.09 | $5.30 | 153.59% | Buy |
| ANGO | AngioDynamics | $6.88 | $15.00 | 118.02% | Buy |
| TFX | Teleflex | $194.43 | $304.36 | 56.54% | Buy |
| ATRC | AtriCure | $34.72 | $49.57 | 42.77% | Buy |
| HAE | Haemonetics | $88.17 | $108.25 | 22.77% | Buy |
| WST | West Pharmaceutical Services | $307.21 | $345.33 | 12.41% | Buy |
| NVST | Envista | $20.61 | $23.11 | 12.13% | Hold |
| ALC | Alcon | $85.81 | $93.89 | 9.42% | Buy |
| HOLX | Hologic | $78.79 | $80.21 | 1.80% | Buy |
| ICUI | ICU Medical | $169.98 | $172.00 | 1.19% | Buy |
| MMSI | Merit Medical Systems | $103.94 | $100.78 | -3.04% | Buy |
| RMD | ResMed | $239.42 | $219.13 | -8.47% | Hold |
| ATR | AptarGroup | $166.69 | $138.00 | -17.21% | Buy |